One of medicine’s costliest treatment areas could become even more pricey as Biogen seeks to layer the company’s $750,000 spinal muscular atrophy drug on top of the $2.1 million-per-patient Novartis gene therapy Zolgensma.
Eli Lilly priced the company’s acute migraine treatment Reyvow at $640 for a pack of eight pills.
Novartis AG, Merck & Co. Inc. and Allergan Plc were among companies that raised U.S. prices on more than 100 prescription medicines, bringing the tally to 445 drugs that will cost more in 2020, according to data analyzed by healthcare research firm 3 Axis Advisors.
Drugmakers including Bristol-Myers Squibb Co., Gilead Sciences Inc. and Biogen Inc. hiked U.S. list prices on more than 50 drugs to begin 2020, bringing total New Year’s Day drug price increases to more than 250, according to data analyzed by 3 Axis Advisors.
Roche Holding AG priced the company’s personalized cancer treatment Rozlytrek at about $17,050 per month, nearly half of the monthly price of a rival drug from Bayer AG and Eli Lilly and Co. that was approved during 2018.
Canada’s main pharmaceutical lobby group urged the government not to wait for drug shortages before responding to U.S. plans to import Canadian drugs, according to documents seen by Reuters.
The U.S. Food and Drug Administration approved Zolgensma, a gene therapy that Novartis called a life-changing medicine, for children younger than 2 years of age who have been diagnosed with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 gene.
Indianapolis-based Eli Lilly announced that the company’s Lispro Injection, an authorized generic version of the life-saving insulin Humalog, is available at pharmacies at a 50 percent lower list price.
A Japanese government panel approved a price of 33.5 million yen ($305,800) for Novartis’ cancer treatment Kymriah, allowing the Swiss drugmaker to press ahead with a campaign to kick-start sluggish sales of the treatment.
England’s National Health Service reached a deal to pay for U.S. drugmaker Biogen Inc.’s expensive spinal muscle atrophy treatment Spinraza.